Idiopathic pulmonary fibrosis(IPF)is the prototype of a large and heterogeneous group of chronic progressive pulmonary disorders.No treatment is able to halt or reverse pulmonary fibrosis,although pirfenidone(Pirf)and...Idiopathic pulmonary fibrosis(IPF)is the prototype of a large and heterogeneous group of chronic progressive pulmonary disorders.No treatment is able to halt or reverse pulmonary fibrosis,although pirfenidone(Pirf)and nintedanib(Nint)have been shown to slow lung function decline and disease progression but with significant side effects.We evaluated the safety and efficiency of GED-0507,an original selective peroxisome proliferator-activated receptor(PPAR)-γmodulator,in a murine model of bleomycin(BLM)-induced pulmonary fibrosis compared to those of Pirf and Nint.Preventive and curative administration of GED-0507 improved the loss of body weight and extension of lung fibrotic lesions.When given as a preventive treatment,GED-0507 also abrogated the mortality rate and histological fibrosis score,as well as the lung levels of hydroxyproline.展开更多
基金Nogra Pharma Ltd.,Dublin,Ireland,for partly funding this study.
文摘Idiopathic pulmonary fibrosis(IPF)is the prototype of a large and heterogeneous group of chronic progressive pulmonary disorders.No treatment is able to halt or reverse pulmonary fibrosis,although pirfenidone(Pirf)and nintedanib(Nint)have been shown to slow lung function decline and disease progression but with significant side effects.We evaluated the safety and efficiency of GED-0507,an original selective peroxisome proliferator-activated receptor(PPAR)-γmodulator,in a murine model of bleomycin(BLM)-induced pulmonary fibrosis compared to those of Pirf and Nint.Preventive and curative administration of GED-0507 improved the loss of body weight and extension of lung fibrotic lesions.When given as a preventive treatment,GED-0507 also abrogated the mortality rate and histological fibrosis score,as well as the lung levels of hydroxyproline.
